Furthermore, HOTAIR inhibition results in higher sensitivity to imatinib
by regulating MRP expression (15).
Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Monday the receipt of the final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Imatinib
Mesylate Tablets in 100mg and 400mg product strengths.
Briefly, 10 [micro]L/well of 50, 100, 150, and 200 [micro]M concentrations of apigenin, luteolin, 5-desmethyl sinensetin, and (as positive control) imatinib
(5, 10, 25, 50 [micro]M) were added, and cells (90 [micro]L/well; [10.sup.5] cells/mL culture medium) were subsequently seeded and incubated for 72 h.
(5,14,15) Research by Chikkodi et al, in 124 newly diagnosed of CML chronic phase patients that received imatinib
, 82.3% patient reached EMR, low-intermediate Hasford score had a higher prediction to reach EMR (p=0,0179).
All the enrolled patients were placed on Imatinib
therapy (400 mg/day) and RT-PCR for BCR ABL1 transcript was repeated after three months.
Dusetzina, Ph.D., from Vanderbilt University in Nashville, Tenn., discuss potential barriers to effective generic price competition for specialty prescription drugs using the case of generic imatinib
. Outpatient pharmacy claims were selected for May 1, 2001, to Sept.
, an inhibitor of KIT that is a platelet-derived growth factor-a (PDGFR-a), came into use as the standard first-line agent for metastatic GIST , and sunitinib is used for patients who are imatinib
refractory. Radiotherapy is not recommended as a treatment modality in the current treatment guidelines  and is only used with palliative intent for bone metastases. This approach is based on previous reports that suggest that radiotherapy is not beneficial in the treatment of GIST  while it is considered a radiotherapy-resistant or minimally responsive entity.,,, However, the results from a few case reports  and some retrospective data  reported that GIST is not uniformly radioresistant and may benefit from radiotherapy.
In this retrospective study, we focus on several potential factors, such as clinicopathological parameters and imatinib
treatment, to predict disease-free survival (DFS) and overall survival (OS) of 62 patients with DGISTs.
It is efficacious in cases of resistance or intolerance to Imatinib
Therefore, we conducted a meta-analysis to elucidate which GIST genotype is the most sensitive to sunitinib following imatinib
is a tyrosine kinase inhibitor that is used in various hematologic malignancies, including idiopathic hypereosinophilic syndrome (IHES) which is a myeloproliferative disorder characterized by sustained, nonreactive, unexplained persistent hypereosinophilia that commonly results in multiorgan dysfunction.